Bystolic (nebivolol) / Menarini, AbbVie - LARVOL DELTA

Cardioprotection without risk? meta-analysis of prophylactic agents in low-risk cancer patients on anthracyclines (ASH 2025) - "We included randomized controlled trials (RCTs) of prophylactic ACE inhibitors, ARBs, beta-blockers, statins, dexrazoxane, or SGLT2 inhibitors in adults without pre-existing cardiovascular risk factors...Agents studied included beta-blockers (nebivolol, carvedilol, bisoprolol), ACE inhibitors (ramipril), ARBs (telmisartan), and spironolactone. Treatment duration ranged from 4 months to 1 year; anthracycline doses reached up to 689 mg/m² (epirubicin) or 536 mg/m² (doxorubicin)...The protective benefit was greater in contexts involving higher cumulative anthracycline doses and concurrent cardiotoxic therapies such as trastuzumab...However, high heterogeneity limits firm conclusions. Given the moderate effect size and heterogeneity, further large-scale, well-formulated trials are essential to identify optimal cardioprotective agents and precise patient selection criteria."

Retrospective data • Breast Cancer • Congestive Heart Failure • Heart Failure • Oncology • Solid Tumor

Diversified, endothelial cell-dependent cancer cell response to hypertensive serum modified by antihypertensive drugs. (PubMed, Sci Rep) - "Serum was collected from hypertensive patients treated with amlodipine, nebivolol, and perindopril for 6 weeks, alongside samples from healthy individuals. In summary, our study demonstrates that antihypertensive therapy, especially with nebivolol, potentially reverses hypertension-induced changes that exacerbate the cancer-promoting phenotype of endothelial cells. This suggests that beyond controlling blood pressure, antihypertensive treatments may also play a role in modulating cancer progression."

Journal • Cardiovascular • Hypertension • Oncology • Pulmonary Arterial Hypertension • ANGPT1 • CDH1 • CXCL1 • CXCL12 • CXCL8 • OCLN • TGFB1

Nebivolol in the therapeutic landscape of heart failure: Mechanisms and clinical outcomes. (PubMed, Vascul Pharmacol) - "Looking ahead, advances in pharmacogenomics, digital phenotyping, and adaptive trial designs may help personalize nebivolol therapy. This review underscores nebivolol's emerging position in the evolving landscape of HF treatment."

Clinical data • Journal • Review • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Oncology • Renal Disease

Post-lanosterol inhibition profile based classification of commonly used prescription medications. (PubMed, Transl Psychiatry) - "Using LC-MS/MS we measured 13 post-lanosterol intermediates in control, DHCR7 +/- and DHCR7-/- human dermal fibroblasts exposed to cariprazine, nebivolol, rotigotine, buspirone, lurasidone, fluoxetine, hydroxyzine, amiodarone, spiroxamine, vilazodone and ziprasidone. In addition, DHCR7 +/- fibroblasts responded with greater sterol profile disruptions to all medications, while DHCR7 fibroblasts from patients with Smith-Lemli-Opitz syndrome showed generally a more plateaued response. Knowing the inhibition profile-based classification of medications that have a sterol inhibiting side effect might ultimately translate into safety recommendations during pregnancy and could be critical for new drug development."

Journal • DHCR7

Evaluation of the Cardioprotective Effect of Nebivolol on Trastuzumab-Induced Cardiotoxicity in Breast Cancer Patients (clinicaltrials.gov) - P2 | N=56 | Recruiting | Sponsor: Ain Shams University

New P2 trial • Breast Cancer • Cardiovascular • Congestive Heart Failure • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor

Impact of β-Blocker Nebivolol versus Bisoprolol Prescription at Discharge on Long-term Clinical Outcomes in ST elevation Myocardial Infarction Patients with Reduced Left Ventricular Ejection Fraction ( (AHA 2025) - "In STEMI patients with reduced LVEF treated with DESs, discharge prescription of Nebivolol was associated with a significantly lower incidence of MACE compared to Bisoprolol, while total death remained similar between the two groups after IPTW adjustment. These findings suggest that Nebivolol may offer additional benefits in reducing MACE in this population."

Clinical • Clinical data • Cardiovascular • Myocardial Infarction

Thiazole pharmacophore-based discovery of novel SGLT2 inhibitors using virtual screening, molecular docking, and molecular dynamics simulation for diabetic nephropathy. (PubMed, SAR QSAR Environ Res) - "Four compounds olodaterol, nebivolol, Z56768840, and Z8314156464 were identified, with olodaterol showing the most stable interactions during a 100 ns molecular dynamics (MD) simulation. NC-1 demonstrated a high pharmacophore fitness score (1.64), favourable docking energy (-11.1 kcal/mol), and stable MD interactions. This integrated computational approach offers a valuable platform for discovering non-glycosidic SGLT2 inhibitors and supports further development of NC-1 for potential treatment of DN."

Journal • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease • Urology

Primary Hyperaldosteronism Presenting Clinically as Classic Pheochromocytoma (KIDNEY WEEK 2025) - "Therapy at the time included irbesartan 300mg daily, nebivolol 20mg daily, amlodipine 10mg daily and hydralazine 10mg three times daily. Symptoms of profuse sweating, palpitations and impending sense of doom are often associated with pheochromocytomas which can also result in hypertension. This case demonstrates how variability can exist in symptomatic burden."

Clinical • Cardiovascular • Endocrine Disorders • Hypertension • Solid Tumor

Medical Management of Pheochromocytoma in a 95-Year-Old Woman: A Case Report of Long-Term Conservative Therapy (KIDNEY WEEK 2025) - "By March 2020, phenoxybenzamine was increased to 10 mg TID; doxazosin 2 mg TID. Metoprolol was added but later changed to nebivolol. Clonidine 0.1 mg PRN was initiated in April 2023...Despite age >90, CKD, and severe aortic stenosis, BP was largely controlled without surgical intervention. Conservative therapy may be a durable and effective alternative in select high-risk patients."

Case report • Clinical • Cardiovascular • Chronic Kidney Disease • Hypertension • Hypotension • Infectious Disease • Pneumonia • Respiratory Diseases • Solid Tumor

Postmarketing Safety Analysis of Nebivolol in Real-World Settings Using Bioinformatics and Disproportionality Analysis With FDA Adverse Event Reporting System (FAERS) Data (ISPOR-EU 2025) - "This real-world post-marketing analysis identified multiple potentially serious adverse reactions to nebivolol, emphasizing the importance of continued pharmacovigilance. The integration of bioinformatics enhances understanding of underlying molecular mechanisms. Further pharmacogenetic studies are warranted to confirm causality and support safer prescribing practices."

Adverse events • Clinical • P4 data • Real-world • Real-world evidence • Cardiovascular • Hypertension • Immunology • IL1B • IL6

Nebivolol-Induced Melena: A Novel Signal Identified Through US Food And Drug Administration Adverse Event Reporting System (FAERS) Database (ISPOR-EU 2025) - "This analysis suggests that melaena may be a potential adverse reaction in patients receiving nebivolol. Healthcare professionals should be vigilant for signs of gastrointestinal bleeding in patients treated with nebivolol. Further epidemiological studies are warranted to validate this signal and clarify its clinical significance."

Adverse events • Cachexia • Gastroenterology • ROR1

The Beta-Blocker Chronicle: From Past Principles to Present Practice - Implications for the Indian Subcontinent. (PubMed, Indian Heart J) - "Among contemporary agents, bisoprolol and nebivolol exemplify next generation β-blockers with high β1-selectivity, favourable tolerability, and cardioprotective effects beyond blood pressure and heart rate control. In Indian context, prescribing trends highlight bisoprolol among the most prescribed β-blockers, reflecting its clinical trust and relevance. Regional experiences affirm the value of β-blockers in optimizing cardiovascular outcomes across the Indian subcontinent."

Journal • Review • Asthma • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Heart Failure • Hypertension • Immunology • Metabolic Disorders • Myocardial Infarction • Nephrology • Pulmonary Disease • Renal Disease • Respiratory Diseases

Modulation of inflammatory and adrenergic pathways in hypertension: effects of β-blockers on cytokine release in Jurkat T cells. (PubMed, Acta Biochim Pol) - "The study results show that propranolol, metoprolol, carvedilol, but not nebivolol, revealed toxic effects on the intact Jurkat cells (pc-p = 0.0001; pc-m > 0.0001; pc-c = 0.0003; pc-n = 0.0525). In contrast, propranolol and metoprolol exhibited more limited activity. These findings suggest that third-generation β-blockers may offer both cardiovascular and immunomodulatory benefits, although further validation in primary immune cells and in vivo models is still required."

Journal • Cardiovascular • Hypertension • IL17A • IL6 • TNFA

Cardioprotective Mechanisms of Beta-Blockers in Myocardial Ischemia and Reperfusion: From Molecular Targets to Clinical Implications. (PubMed, Int J Mol Sci) - "Third-generation compounds, carvedilol and nebivolol, demonstrate additional antioxidant and vasodilatory benefits compared with first- and second-generation agents; however, no consistent class-wide effect exists across most pathways. The evidence base remains fragmented, often derived from agent- or context-specific studies in heterogeneous populations, with uncertainty surrounding optimal timing of intervention. By bridging mechanistic understanding with clinical outcomes, this review highlights the importance of standardized assessment of BB effects, the development of personalized treatment approaches, and the pursuit of future research to address ongoing translational gaps."

Journal • Review • Cardiovascular • Coronary Artery Disease • Heart Failure • Inflammation • Myocardial Ischemia • Reperfusion Injury

The Impact of Commonly Used Medications on Erectile Dysfunction: Which Drugs Deserve Particular Attention? (PubMed, Cureus) - "Beta-blockers, especially older non-selective agents, contribute to ED by causing vascular constriction and hormonal alterations, while newer agents like nebivolol may improve erectile function via nitric oxide release. Diuretics, particularly thiazides, show mixed evidence regarding their effect on erectile function, though aldosterone receptor antagonists such as spironolactone are linked to antiandrogenic side effects...Understanding these drug-related risks is crucial for clinicians to tailor therapies that minimize sexual side effects, thereby enhancing patient adherence and overall quality of life. Further research is warranted to clarify mechanisms and develop effective management strategies for medication-induced ED."

Journal • Review • Cardiovascular • CNS Disorders • Erectile Dysfunction • Psychiatry • Schizophrenia • Sexual Disorders

BETA-BLOCKERS ARE ASSOCIATED WITH LOWER RISK OF PANCREATIC CANCER IN PATIENTS WITH TYPE 2 DIABETES: A POPULATION-BASED COHORT STUDY (UEGW 2025) - "Primary exposure was beta-blocker use (e.g., acebutotlol, atenolol, bisoprolol, carvedilol, celiprolol, esmolol, labetalol, metoprolol, nadolol, nebivolol, pindolol, propranolol, and sotalol)...Adjusted hazard ratios (aHRs) were derived from multivariable Cox models adjusting for 31 covariates: age, sex, smoking status, alcohol use disorder, body index mass, glycemic control (in terms of time-weighted mean HbA1c), pancreatitis, cholangitis, colectomy, Charlson's comorbidity index, metabolic and cardiovascular comorbidities, and concomitant medications (aspirin, non-steroidal anti-inflammatory drugs, statins, and other antidiabetics)... Beta-blocker use was associated with a lowered risk of PC among patients with newly diagnosed T2D, in a dose- and duration-dependent manner."

Clinical • Addiction (Opioid and Alcohol) • Diabetes • Gastrointestinal Disorder • Hepatology • Metabolic Disorders • Oncology • Pancreatic Cancer • Pancreatitis • Solid Tumor • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Polydopamine and hyaluronic acid-coated dual-responsive silica nanoparticles for targeted atherosclerosis imaging and therapy. (PubMed, Nanoscale Adv) - "Nebivolol (NB), a third-generation beta-blocker clinically used to treat hypertension and heart failure, exerts potent antioxidative activities by inhibiting reactive oxygen species (ROS) production and scavenging ROS...Moreover, the silanols on the silica surface and the HA coating on the MSNs enable accelerated drug release from NB/SPDA@HA nanoparticles in response to the acidic and hyaluronidase-rich microenvironment in the plaque. Taken together, the dual-responsive NB/SPDA@HA nanotheranostic platform represents a promising nanomedicine for targeted atherosclerosis imaging and therapy."

Journal • Atherosclerosis • Cardiovascular • Congestive Heart Failure • Dyslipidemia • Heart Failure • Hypertension • Inflammation • CD44

Minoxidil and nebivolol restore aortic elastic fiber homeostasis in diabetic mice via potassium channel activation. (PubMed, Front Physiol) - "Minoxidil and nebivolol restore EF integrity and limit vascular aging in diabetic mice via K+ channel opening and FOXO1 repression. These findings highlight potassium channel-FOXO1 signaling as a therapeutic axis to counteract diabetic vascular complications."

Journal • Preclinical • Cardiovascular • Diabetes • Metabolic Disorders

Comparative Efficacy And Safety Of Cardioprotective Drugs In Patients With Breast Cancer Undergoing Chemotherapy: A Frequentist Network Meta-analysis (HFSA 2025) - "Bisoprolol (MD: -3.03%, SUCRA: 0.5561, P=0.0190) and Candesartan (MD: -2.93%, SUCRA: 0.5524, P=0.0013) showed moderate yet significant benefits. Spironolactone, Nebivolol, and Lisinopril+Bisoprolol showed significant protective effects on LVEF in breast cancer patients receiving chemotherapy. Spironolactone was identified as the most effective option, whereas Carvedilol, Metoprolol, and Perindopril had limited benefit. These findings support using Spironolactone, Nebivolol, or combination therapies for cardioprotection during chemotherapy."

Retrospective data • Breast Cancer • Oncology • Solid Tumor

Large left internal jugular vein determined during cardiac surgery: A case report. (PubMed, Saudi J Anaesth) - "The patient had many comorbidities, so she was on antihypertensive (nebivolol), antithrombotic (rivaroxaban), and antidiabetic (insulin) medications. Although right IJV is usually preferred for CVC where central intravenous access is required, it is advisable to evaluate the left IJV when the right one has a small diameter and there is a significant overlapping of right CA. In these cases, the choice for CVC side should be based on the data which is obtained from both sides."

Journal • Anesthesia • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Concomitant vitiligo, psoriasis and hidradenitis suppurativa: a window into shared immune dysregulation (EADV 2025) - "His comorbidities included arterial hypertension, managed with Nebivolol/Hydrochlorothiazide 5/12.5 mg once daily and Amlodipine 5 mg once daily...HS treatment included zinc gluconate 15 mg three times daily, topical clindamycin, and antiseptic washes with chlorhexidine 4% and polyhexanide 0.1%... The coexistence of vitiligo, psoriasis and hidradenitis suppurativa in a single patient suggests a potential overlap in autoimmune and autoinflammatory pathogenic pathways. Understanding these shared mechanisms may support the development of more integrated and effective treatment strategies."

Cardiovascular • Dermatology • Genetic Disorders • Hidradenitis Suppurativa • Immunology • Infectious Disease • Inflammation • Obesity • Psoriasis • Pulmonary Arterial Hypertension • Vitiligo • CRP • IL17A • IL1B • TNFA

Pharmacological interventions to prevent cardiotoxicity in patients undergoing anthracycline-based chemotherapy: a network meta-analysis. (PubMed, Front Cardiovasc Med) - "In terms of diastolic function (E/A ratio), Nebivolol outperformed other β-blockers [MD = 0.23, 95% CI (0.09, 0.37)]...According to the research findings, Spironolactone and Dexrazoxane significantly prevent the decline in LVEF and the occurrence of cardiac events compared to placebo or conventional chemotherapy, with statistical significance. This discovery provides valuable reference for the clinical prevention of anthracycline chemotherapy-induced cardiotoxicity, contributing to the optimization of treatment regimens, reduction of cardiac toxicity risks in patients, and improvement of prognosis. PROSPERO (CRD42024567684)."

Journal • Retrospective data • Review • Cardiovascular • Oncology

Nebivolol prevents coronary artery spasm by upregulating voltage-gated potassium channels via protein kinase A. (PubMed, Eur J Pharmacol) - "Nebivolol (Neb) relaxes coronary arteries and increases coronary artery blood flow, but the underlying mechanisms need further elucidation. Inhibitor study showed that Kv channel inhibitor 4-aminopyridine (4-AP, 1 mM) and protein kinase A (PKA) inhibitor H-89 (1 μM) attenuated Neb-induced RCA relaxation and Kv current increment in RCA ASMCs, while p38 MAPK inhibitor SB239063 (1 μM) had no effect. In summary, the present study demonstrated that Neb relaxed RCAs through PKA-mediated upregulation of Kv channels in RCA ASMCs."

Journal

Nebivolol Mitigates the Pro-Oxidative and Pro-Inflammatory Effects of Cyclophosphamide in the Heart. (PubMed, Fundam Clin Pharmacol) - "In conclusion, nebivolol demonstrates cardioprotective effects against the toxicity of CP by reducing pro-oxidative and pro-inflammatory responses. Thus, nebivolol may represent a novel clinical approach for managing the cardiotoxic effects associated with CP."

Journal • Cardiovascular • MT-CO2

Target the Heart: A New Axis of Alzheimer's Disease Prevention. (PubMed, J Dement Alzheimers Dis) - "Co-administering a low dose of cyclosporine A with select cardiac drugs could be a potentially effective treatment strategy for preventing Alzheimer's disease occurrence and simultaneously treating cardiovascular dysfunction, while mitigating the side effects associated with higher doses of cyclosporine A. Given that heart disease precedes Alzheimer's disease in many patients, physicians may be able to create a treatment regimen that addresses both con-ditions. Our results suggest that a calcineurin inhibitor combined with simvastatin, irbesartan, cilostazol, doxazosin, or nebivolol is the most promising candidate for future exploration."

Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Dementia • Heart Failure